Close Menu

You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.

Home » Business, Policy & Funding » Business News » Genalyte Raises $44M in Series C Financing

Genalyte Raises $44M in Series C Financing

Aug 18, 2015
|
staff reporter

NEW YORK (GenomeWeb) – San Diego-based diagnostics firm Genalyte today announced it has completed a $44M Series C financing round.

Khosla Ventures joined previous investors Redmile Group, Claremont Creek Ventures, and BioMed Ventures in the round.

Genalyte's CE-marked Maverick Detection System is intended for multiplexed, blood-based, point-of-care diagnostic testing. The firm said in a statement that it can provide results in 15 minutes. The platform is for research use only in the US.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Scan

Earlier in the US

An analysis of blood donations suggests SARS-CoV-2 was present in the US weeks earlier than thought, according to NPR.

How the Proteins Shape Up

The Guardian reports that DeepMind Technologies' AlphaFold can predict how proteins fold.

Who's to Be First?

CNBC reports that a US Centers for Disease Control and Prevention advisory panel is to vote on how to distribute COVID-19 vaccines.

PNAS Papers on Ovarian Cancer, Retrotransposon Insertions in Cancer, Malaria Mosquitoes

In PNAS this week: targeting progesterone signaling in ovarian cancer, LINE-1 retrotransposition events in adenocarcinomas, and more.

What's Popular?

In Molecular Diagnostics

  1. Thermo Fisher Scientific Raises Q4 and 2020 Revenue, Earnings Guidance

  2. Illumina, PierianDx Expand Partnership on Cancer Panel Test Reporting

  3. Cepheid, Roche Coronavirus Tests Get FDA Emergency Use Authorization

  4. UnitedHealthcare to Cover NIPT for Average-Risk Pregnancies

  5. Progenity to Raise $100M in Separate Public Stock, Private Senior Notes Offerings

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2020 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.